Trial reportJournal of cosmetic dermatology2025
Effectiveness and Safety of Combined Use of Home-Based Radiofrequency Device and Arbutin Cream in Melasma and Facial Rejuvenation.
Trial report in Journal of cosmetic dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- A Retrospective Analysis of Radiofrequency Microneedling for Melasma Management in the Japanese Population.Clinical, cosmetic and investigational dermatology · 2026Article
- The Efficacy and Safety of Radiofrequency Microneedling for Melasma: A Systematic Review and Qualitative Evidence Synthesis.Aesthetic surgery journal. Open forum · 2026Review
- Efficacy and Safety Evaluation of Microneedling Combined with Tranexamic Acid-Arbutin Liquid Excipients in the Treatment of Melasma: A Retrospective Study.Clinical, cosmetic and investigational dermatology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundMelasma and facial aging are prevalent dermatological concerns. The combined use of a home-based radiofrequency (RF) device and a topical depigmentation agent, such as an arbutin-based cream, has shown potential in addressing both conditions.
aimsThis study evaluated the effectiveness and safety of combining a home-based RF device with arbutin cream to treat melasma and facial aging.
methodsThis single-center, open-label study included 38 participants. The treatment involved using a home-based RF device alongside an arbutin cream three times a week for 4 weeks, followed by a 4-week rest period. Key outcomes included changes in modified Melasma Area and Severity Index (mMASI) scores, melanin index (MI), erythema index (EI), facial wrinkles, skin texture, and periorbital dermal thickness. The participants also provided a self-assessment of the treatment efficacy.
resultsAfter 4 and 8 weeks of treatment, compared with baseline, the mMASI scores decreased by 20.8% and 25.6%, whereas the MI decreased by 22.0% and 22.8%, respectively. The EI decreased by 5.94% and 6.86%, facial wrinkles decreased by 30.9% and 35.9%, and skin texture scores decreased by 19.7% and 21.4% at 4 and 8 weeks posttreatment, respectively. Significant improvements in periorbital dermal thickness and subcutaneous tissue thickness were observed after combined RF and arbutin cream treatment. None of the 38 participants experienced adverse events, and all reported satisfaction with the results.
conclusionThe combination of a noninvasive home-based RF device and arbutin cream is effective in improving melasma and achieving facial rejuvenation, offering a safe and patient-friendly treatment option.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.